VIVANZA share price, P/E, ROE & financials

As of 6 Nov 2026, Vivanza Biosciences trades at 12.3× trailing earnings, below the industry P/E of 28.7×, and the shares are 46% below their 52-week high. Sales grew 87% a year over 3 years while net profit fell 13%, with ROCE of 16% and ROE of 9.5%. Debt is 2.34× equity. It is a small-cap company with a market cap of ₹5.92 Cr, ranked 153rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 27% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹1.43
Day high: ₹1.48
Day low: ₹1.43
Prev. close: ₹1.43
Volume: 5.7K

Health check

1 good · 2 fair · 3 to check

ReturnsBehind
−27.4% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 12.3 vs industry 28.7.
GrowthSteady
Sales +86.7%, profit −13.0% a year over 3 years.
ProfitabilityAverage
ROCE 15.7% vs peer median 17.9%.
Balance sheetStretched
Debt 2.34× equity, interest covered 2.9×, Piotroski 5 of 9.
Red flags3 to check
Debt is 2.34× equity.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹5.92 Cr, #153 of 154 in its industry by size.

Defensive

Beta 0.35 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹117 Cr · profit ₹0 Cr

Market cap: ₹5.92 Cr; Small cap
P/E: 12.3; Industry 28.7
Price to book: 1.39; Peers 4.99
Dividend yield: 0.00%
ROE: 9.5%; Peers 14.7%
ROCE: 15.7%; Peers 17.9%
Debt to equity: 2.34; Debt ₹10 Cr
EPS (TTM): ₹0.12
OPM (TTM): 0.4%; Net margin 0.4%
Sales growth: +3.9%; Latest quarter vs a year ago
Profit growth: +68.6%; Latest quarter vs a year ago
Price to sales: 0.05; EV/EBITDA 16.0

Strengths

Quarterly profit up 68.6% on a year ago.
P/E of 12.3 against an industry P/E of 28.7.

Risks to check

Debt is 2.34× equity.
46% below its 52-week high.
Interest coverage of only 2.7×.

Derived automatically from reported figures. Not a recommendation.

About Vivanza Biosciences

Vivanza Biosciences Limited engages in the manufacturing and sale of pharmaceutical products in India. It offers pharmaceuticals in various categories; injectable products, including antifungals, antibiotics, antivirals, and other products for hospital and clinical use; Vivanza medical gloves for medical and surgical use; therapeutic index injection; and veterinary products and feed. The company was incorporated in 1982 and is headquartered in Ahmedabad,…

Headquarters: Ahmedabad
Employees: 6
Sector: Healthcare
ISIN: INE984E01035
Website: vivanzabiosciences.com

Price range

52 weeks

₹1.30₹2.72

Today

₹1.43₹1.48

Avg volume (3M): 24.3K
1-year return: minus 27.4%
From 52-week high: minus 45.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.87%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.30%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.81%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.59%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.93%	minus 6.6%
VIVANZAVivanza Biosciences	1.48	plus 3.50%	6	12.3	1.39	15.7%	9.5%	0.4%	86.7%	−13.0%	0.00%	minus 27.4%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.59%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
8.9	55.4	45.3	6.4	9.3
8.8	54.8	45	6.6	9.4
0.1	0.6	0.2	−0.2	−0.1
1.7%	1.1%	0.5%	−3.7%	−0.8%
0	0	0.1	0	0.4
0.1	0	0.1	0.1	0.1
0	0	0	0	0
0.1	0.6	0.2	−0.3	0.2
–	–	–	−49.5%	19.6%
0.1	0.6	0.2	−0.5	0.1
0.02	0.14	0.05	-0.11	0.04

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +86.7%
Profit CAGR 3Y: −13.0%
EPS CAGR 3Y: −12.6%
ROE: 9.5%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
17.8	27.8	7.4	116
–	+56.3%	minus 73.3%	+1461.4%
17.1	26.7	7.7	115
0.7	1.1	−0.3	0.7
4.1%	4.0%	−4.2%	0.6%
0.4	0	0	0
0.4	0.4	0.4	0.3
0	0	0	0
−0	−0	−0	0.1
0.7	0.7	−0.7	0.5
16.5%	21.3%	−1.3%	27.5%
0.6	0.5	−0.7	0.4
–	minus 8.5%	minus 223.2%	–
0.15	0.01	-0.17	0.10

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
4	4	4	4
0.1	0.6	−0	0.4
8	5.2	8.7	10.2
10.4	9.7	3.8	7.5
22.5	19.5	16.5	22.1
0.7	0.7	0.7	0.8
0	0	0	0
0.1	0.2	0.1	0.1
21.7	18.6	15.6	21.2
22.5	19.5	16.5	22.1

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−0.9	2	−2.5	−2.6
–	−0	−0	−0.1
1	−2	2.5	2.7
0.1	0	−0	−0.1
–	−0	−0	−0.1
−0.9	2	−2.5	−2.7

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you